VANCOR

Pre-Launch

vancomycin hydrochloride

ANDAINJECTIONINJECTABLE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

VANCOR (vancomycin hydrochloride) by Pfizer is clinical pharmacology vancomycin is poorly absorbed after oral administration. Approved for serious, severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci.

Drug data last refreshed 2w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…

Worked on VANCOR at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

VANCOR

Mechanism of Action

Indications (2)